Table 1 General characteristics of the study population at referral
Variables | Total | Gender | P | Stage | P | ||||
|---|---|---|---|---|---|---|---|---|---|
Male | Female | G3a | G3b | G4 | G5 | ||||
N (%) | 156 (100.0) | 80 (51.3) | 76 (48.7) | Â | 13 (8.3) | 20 (12.8) | 32 (20.5) | 91 (58.3) | Â |
Age (years), Mean ± SDa | 45.4 ± 12.1 | 48.3 ± 11.8 | 42.4 ± 11.6 | 0.002 | 46.6 ± 14.9 | 49.0 ± 12.8 | 43.2 ± 12.7 | 45.3 ± 11.2 | 0.394 |
Age (years), Min-Max | 22–82 | 25–82 | 22–72 |  | 26–72 | 28–70 | 25–82 | 22–77 |  |
Marital status, n (%) | |||||||||
 Married | 87 (55.8) | 58 (72.5) | 29 (38.2) |  | 9 (69.2) | 9 (45.0) | 17 (53.1) | 52 (57.1) |  |
 Single | 53 (34.0) | 17 (21.3) | 36 (47.4) |  | 3 (23.1) | 8 (40.0) | 13 (40.6) | 29 (31.9) |  |
 Divorced | 2 (1.3) | 1 (1.3) | 1 (1.3) |  | 0 (0.0) | 0 (0.0) | 1 (3.1) | 1 (1.1) |  |
 Widow | 14 (9.0) | 4 (5.0) | 10 (13.2) | < 0.001 | 1 (7.7) | 3 (15.0) | 1 (3.1) | 9 (9.9) | 0.784 |
Employment status, n (%) | |||||||||
 Unemployed | 56 (35.9) | 11 (13.8) | 45 (59.2) |  | 6 (46.2) | 4 (20.0) | 12 (37.5) | 34 (37.4) |  |
 Public agent | 10 (6.4) | 8 (10.0) | 2 (2.6) |  | 0 (0.0) | 1 (5.0) | 1 (3.1) | 8 (8.8) |  |
 Private sector | 37 (23.7) | 29 (36.3) | 8 (10.5) |  | 5 (38.5) | 5 (25.0) | 8 (25.0) | 19 (20.9) |  |
 Informal sector | 39 (25.0) | 18 (22.5) | 21 (27.6) |  | 1 (77) | 6 (300) | 8 (25.0) | 24 (26.4) |  |
 Retired | 14 (9.0) | 14 (17.5) | 0 (0.0) | < 0.001 | 1 (7.7) | 6 (30.0) | 8 (25.0) | 24 (26.4) | 0.548 |
Co morbidity, n (%) | |||||||||
 Hypertension | 57 (36.5) | 25 (31.6) | 32 (42.1) | 0.177 | 4 (33.3) | 6 (30.0) | 10 (31.3) | 37 (40.7) | 0.690 |
 Diabetes | 28 (17.9) | 18 (22.8) | 10 (13.2) | 0.119 | 2 (16.7) | 6 (30.0) | 7 (21.9) | 13 (14.3) | 0.372 |
 HCVb coinfection | 12 (7.7) | 7 (8.8) | 5 (6.6) | 0.611 | 1 (7.7) | 2 (10.0) | 1 (3.1) | 8 (8.8) | 0.742 |
 Chronic use of NSAIDc | 9 (5.8) | 4 (5.1) | 5 (6.6) | 0.744 | 1 (8.3) | 1 (5.0) | 1 (3.1) | 6 (6.6) | 0.876 |
 HBVd coinfection | 6 (3.8) | 5 (6.3) | 1 (1.3) | 0.211 | 0 (0.0) | 2 (10.0) | 3 (9.4) | 1 (1.1) | 0.070 |
Background nephropathy, n (%) | |||||||||
 HIVANe | 43 (27.6) | 26 (32.5) | 17 (22.4) |  | 4 (30.8) | 5 (25.0) | 6 (18.8) | 28 (30.8) |  |
 Chronic glomerulonephritis | 24 (15.4) | 9 (11.3) | 15 (19.7) |  | 1 (7.7) | 5 (25.0) | 5 (15.6) | 13 (14.3) |  |
 Diabetes | 22 (14.1) | 15 (18.8) | 7 (9.2) |  | 1 (7.7) | 6 (30.0) | 4 (12.5) | 11 (12.1) |  |
 Hypertension | 21 (13.5) | 7 (8.8) | 14 (18.4) |  | 3 (23.1) | 2 (10.0) | 12 (37.5) | 21 (23.1) |  |
 Chronic interstitial nephritis | 7 (4.5) | 3 (3.8) | 4 (5.3) |  | 1 (7.7) | 0 (0.0) | 1 (3.1) | 5 (5.5) |  |
 Polykystosis | 1 (0.6) | 1 (1.3) | 0 (0.0) |  | 0 (0.0) | 1 (5.0) | 0 (0.0) | 0 (0.0) |  |
 Unknown | 38 (24.4) | 19 (23.8) | 19 (25.0) | 0.139 | 3 (23.1) | 2 (10.0) | 12 (37.5) | 21 (23.1) | 0.242 |
Known HIVe infected, n (%) | 109 (69.9) | 56 (70.0) | 53 (69.7) | 0.971 | 8 (61.5) | 16 (80.0) | 21 (65.6) | 64 (70.3) | Â |
HIV infection vintage (month)g | 36 (11–96) | 36 (12–108) | 36 (10.3–96) | 0.856 | 24 (1–144) | 15 (4–48) | 24 (7.5–60) | 36 (12–108) | 0.251 |
Use of cARTf, n (%) | 76 (48.7) | 36 (45.0) | 40 (52.6) | 0.340 | 7 (53.8) | 10 (50.0) | 11 (34.4) | 48 (52.7) | Â |
Duration on cARTfg | 36 (6.8–96) | 36 (12–99) | 36 (6–96) | 0.879 | 40 (18.3–90) | 8 (2–79.5) | 48 (4–72) | 36 (9.8–105) | 0.797 |
Drug regimen, n (%), n = 76 | |||||||||
 1st line | 65 (85.5) | 33 (91.7) | 32 (80.0) |  | 6 (85.7) | 8 (80.0) | 8 (72.7) | 43 (89.6) |  |
 2nd line | 11 (14.5) | 3 (8.3) | 8 (20.0) | 0.199 | 1 (14.3) | 2 (20.0) | 3 (27.3) | 5 (10.4) |  |
CD4 countg, n = 88 | 241 (117–438) | 256 (138–387) | 216 (96–535) | 0.619 | 101 (66–376) | 176.5 (137–333.3) | 278 (117.3–549) | 271 (120–451) | 0.456 |